Abstract:Key PointsHistone deacetylase inhibitors are novel anticancer agents that induce tumour cell death, differentiation, and/or cell cycle arrest. As well as their intrinsic effects on tumour cells, histone deacetylase inhibitors may additionally affect neoplastic growth and survival by regulating host immune responses and tumour vasculature.The pleiotropic cellular effects of HDACi can act cooperatively to mediate potent anti-tumour activities; however, the molecular processes underlying these effects of HDACi remain to be fully elucidated.The activity of diverse non-histone proteins can be regulated by acetylation indicating that HDACi may have a much broader effect on cellular physiology than originally understood. Altered gene expression through the effects of HDACi on the activity of transcription factors and transcription-independent effects of HDACi are also important in their anticancer activities.In preclinical studies, several classes of HDACi have been found to have potent anticancer activities, and some have demonstrated promising therapeutic potential in early clinical trials for haematological malignancies such as cutaneous T-cell lymphoma, myelodysplastic syndromes and diffuse B-cell lymphoma.While HDACi show promise as single agent anticancer drugs, their use in combination with other agents may prove to be their most useful application. Already, HDACi have been shown to function synergistically with a host of structurally and functionally diverse chemical compounds and biologically active polypeptides.

HDACi: cellular effects, opportunities for restorative dentistry

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

The emerging roles of HDACs and their therapeutic implications in cancer

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Targeting histone deacetylases: Emerging applications beyond cancer

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Advances in the Application of Histone Deacetylase Inhibitors in Eye Disease

Histone deacetylases and cancer: causes and therapies

Targeting histone deacetylase in cardiac diseases

New Development of HDAC Inhibitors As Anti-Cancer Agents

Histone Deacetylases (HDACs) Roles in Inflammation-mediated Diseases; Current Knowledge

Anticancer activities of histone deacetylase inhibitors

The Antiangiogenesis Role of Histone Deacetylase Inhibitors: Their Potential Application to Tumor Therapy and Tissue Repair

Recent developments of HDAC inhibitors: Emerging indications and novel molecules

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy

Targeting the Zinc-Dependent Histone Deacetylases (HDACs) for Drug Discovery

Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors

HDACi: molecular mechanisms and therapeutic implications in the innate immune system

Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis.

Histone Deacetylase: A Potential Therapeutic Target For Fibrotic Disorders

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.